

COSA NEWS



Sandro V Porceddu, President, COSA

President's Report

The new COSA Strategic Plan was launched to the members via electronic correspondence and is now available on the COSA website. During their deliberations of this financial year's budget, the Board considered plans from many COSA Groups for activities aligned with COSA's new strategy. You can read the detail in the Group reports and I've listed some below:

- With the commitment of the AYA Group Chair Wayne Nicholls and the highly motivated Executive Committee, the AYA Group will continue its work on developing a plan for AYA research and a strategy for AYA services more broadly.
- Following successful mentoring programs in previous years, the Board has once again approved an Asia-Pacific Mentoring Fellowship.
- Building on the success of the Geriatric Oncology Group and their work on last year's ASM, Christopher Steer and his Group will hold a strategic planning day to develop a plan for future activities and a strategy to continue to engage the membership's interest in this field. Work already underway includes a project to inform geriatric assessment in oncological practice.
- Under the leadership of Sabe Sabesan, the Regional and Rural Group will host a meeting of the Regional Cancer Centre Directors. Feedback received from the Directors has been very positive, with many excited about the opportunity to come together in a COSA facilitated forum.

One of the four pillars in the COSA Strategic Plan is Advocacy – for COSA to advocate for matters affecting cancer service delivery, policy and care. In the coming year we will work closely with Cancer Council Australia (CCA) on the development of a joint “National

Cancer Care Policy”. CCA and COSA have a long and successful history of joint public policy development and promotion. Highlights have included work on:

- The Optimising Cancer Care report
- The regional cancer centres initiative
- Senate inquiries into cancer service delivery
- Many joint submissions to government consultations over more than a decade, focused on issues such as the health reform agenda, reviews of health and medical research policy
- Conferences focused on issues such as rural/regional services, adolescent and young adult cancer services etc

A joint CCA/COSA National Cancer Care Policy will build on the development of a comprehensive, evidence-based public policy agenda on supportive and clinical cancer care.

In other matters, Marie Malica and I recently met with Helen Zorbas at Cancer Australia for initial discussions around the development of cancer care standards. It is pleasing to see high level groups like Cancer Australia and Cancer Council Australia continue to engage COSA on such important national cancer control issues.

I am delighted to announce that the Board recently appointed Mr Peter Dowding and Ms Felicity Shaw as co-opted Board members with corporate governance and legal expertise. We were impressed by the strong field of candidates in response to our advertisement with the Australian Institute of Company Directors who are eager to work with COSA to help us meet our objectives and work within our new governance requirements as a company limited by guarantee.

President's Report Continued

As always I remain keen to hear from the membership on your ideas for how COSA can help improve cancer care and control. Please feel free to contact me or Marie with any comments or suggestions at cosa@cancer.org.au.

Sandro V Porceddu
President

Executive Officer's Report

COSA Annual Scientific Meeting 2014

I hope to see you all at the ASM in Melbourne this December. We moved our schedule slightly from the traditional second week of November to the first week of December for the exciting opportunity to collaborate with the UICC World Cancer Congress. The COSA ASM will run from Tuesday 2 to Thursday 4 December, and the WCC from Thursday 4 to Saturday 6 December. This means that Thursday will be a joint day between COSA and the WCC. Delegates can either register for the COSA ASM, the WCC, or both. Discounts are on offer if people register for both, and on the joint day delegates will be free to move between all sessions.

The detailed ASM program is now available online. Even though our disease focus is on lung cancer and metastatic disease, I am sure there will be many sessions of interest to COSA members treating other diseases. The themes of survivorship, palliative and supportive care are important for all cancer health professionals and cancer patients, so I am certain the program will appeal.

The opening plenary highlights the challenges of managing oligometastatic disease – something new for the COSA ASM. Bruce Mann will chair and provide an introduction to oligometas; Rod Hicks will present on the limitations of imaging in characterising this entity; Ben Solomon will talk about tailoring systemic treatments; Normand Laperriere will discuss the role of radiotherapy for oligometas; and Nathan Cherney's presentation will focus on how much treatments help in metastatic lung cancer using the ESMO Clinical Benefit Scale.

Bogda Koczwara will chair the Tuesday afternoon plenary delving into what works in the care of cancer survivors. Mary McCabe will provide an introduction to cancer survivorship and the standards of survivorship care; David Weller will talk about the new roles for GPs in cancer survivorship; Kerry Courneya will present on physical activity for symptom control through to survivorship; and Irene Higginson will discuss outcome measures in survivorship.

On Wednesday the program will focus on lung cancer. In addition to the very informative concurrent sessions throughout the day, we will open with a plenary on recent improvements in lung cancer care. Matthew Peters will open with the current state of lung cancer globally; Thomas Lynch will present on targeted therapies for NSCLC; Harvey Pass will discuss new surgical techniques; David Ball shares his wisdom

on radiotherapy for lung cancer; and Thomas Jagoe will enlighten us with new perspectives on symptom management during treatment for advanced lung cancer.

Thursday 4 December is our joint day with the World Cancer Congress and will open with a joint plenary on sustainable systems; and we will close with the hot topic of "New cancer drugs: Do the benefits justify the costs?"

In the Presidential Lecture, Jim Bishop will provide the Australian perspective on comprehensive cancer centres – who better given his current role as Executive Director of the Victorian Comprehensive Cancer Centre.

Don't forget to register for one of the Clinical Professional Day workshops being held on either Monday 1 or Friday 5 December:

- Adolescent and Young Adult Cancers (AYA) workshop
- Next Generation Pathology: At the heart of cancer care and research
- COSA Cancer Pharmacists Clinical Professional Development Workshop
- Targeting Malnutrition in the Cancer Setting - Strategies and Initiatives to Improve Outcomes
- What's new in Psycho-oncology?

COSA Annual Scientific Meeting 2015

I am delighted to announce that the 2015 ASM will be held in Hobart at the Grand Chancellor Hotel, 17-19 November 2015, so mark the dates in your diary now!

Louise Nott and Allison Black, medical oncologists at Royal Hobart Hospital, have

kindly agreed to co-convene the meeting. They have floated some great program ideas already and we are considering a rare cancers theme. We are in the process of convening the local organising committee so please drop me a line if you have any ideas or would like to get involved.

Hobart has a lot to offer in terms of a destination, not just for a conference. So why not plan a family holiday in Tasmania after the ASM. I can highly recommend Tasmania if you haven't visited in recent years. There is something for everyone – food, wine, art, heritage, national parks, walks and hikes for all levels of fitness.

Other COSA educational opportunities

One of COSA's core goals is to meet the educational needs of the membership. Obviously the ASM is our key educational event but we are also exploring other ways and are keen to hear from you. We will be undertaking a survey of the membership soon, but I'd like to hear from you in advance if you have any burning ideas.

Recently COSA hosted the ACT and NSW Oncology Workshop (ACTNOW) in Bowral, 2-4 May 2014. This biennial event is hosted by COSA with financial support from Roche through an educational grant. This unique meeting focuses on a broad range of topics within medical oncology as well as key aspects of patient care across the spectrum of cancer care and general medicine. In attendance was a mix of 44 medical oncologists and advanced trainees.

Delegates learned about new advances in HER 2 positive breast cancer and the new molecular biomarkers in colorectal cancers. The increasing incidence of obesogenic cancers was highlighted

as well as an organised approach to dermatological conditions in cancer patients. Updates on how to approach difficult conversations around survival prognostication, discussing high cost drugs and financial toxicity and engaging patient and partners concerns on sexual health were well covered.

The role of complementary and alternative medicines and the role of meditation and mindfulness in aiding patient recovery after treatment were highlighted. A Journal Club and critical appraisal of practice changing publications generated discussions around adoption of these measures within units.

As you can see ACTNOW provides an opportunity for delegates to learn about topics not presented at traditional oncology conferences in a relaxed and engaging environment. We hope to offer similar opportunities to COSA members in other states in the future.

Staff changes at COSA

Fran Doughton returned from maternity leave in May, and we said goodbye to Rachael Babin as her 12 month contract came to a close.

Rhonda DeSouza has assured me she will also return from her maternity leave after giving birth to Abigail earlier this year. It wouldn't be a COSA report if I didn't announce another COSA baby – Hayley Griffin will be taking maternity leave again in October to have her second baby. We are very fortunate to have Chantal Gebbie on the team who is very capably covering many of the COSA projects.

Marie Malica
Executive Officer

Introducing COSA's newest Board Members

Peter Dowding



Peter is Co-founder and Managing Director of Propel Investments, a mid-market private equity firm based in Sydney and established in 2007. He has over 25 years experience in the private equity sector and has been a board member on several investments including Landis+Gyr Holdings, Bledisloe, Baycorp Collection Services, Hudson Building

Supplies, Pacific Nursing Solutions, Wizard Mortgage Corporation, MediHerb, International Parking Group, The PAS Group, United Energy, Presence Online and AWT International.


Prior to this he was with the DB Capital Partners business, the private equity arm of Deutsche Bank. He completed several investments and was responsible for raising and managing two funds and then led the business prior to a management buy-out in 2007, which resulted in the formation of Propel Investments.

He was Chairman of the Australian Private Equity and Venture Capital Association in 2005 and a council member from 2003 to 2006.

Peter holds a Bachelor of Science in Civil Engineering (Hons) from the University of Nottingham and a Masters of Business Administration from the University of Bath.

COSA asked Peter what had motivated him to join the board
"Firstly I have a strong interest in the sector, both for personal and professional reasons. Secondly the board role offers an opportunity to apply my board skills and experience in the not for profit sector. I look forward to participating in COSA and learning more about the oncology sector."


Felicity Shaw



Felicity is a senior lawyer with over 15 years experience in the global financial services sector. She is currently special counsel and chair of the corporate responsibility group at the Export Finance and Insurance Corporation (Efic), a Commonwealth agency that finances Australian exporters. Before joining Efic in 2005, she held legal roles with Deutsche Bank and multinational law

firms in Sydney, London and Madrid. Felicity holds a Bachelor of Science, a Bachelor of Laws (Hons) and a Masters of Environmental Law from Sydney University.

"I am delighted to join the COSA Board as it presents an ideal opportunity to contribute my legal and governance expertise in a meaningful and personally important way. As a former patient and carer for family members and friends, I have a first-hand appreciation for the tremendous work that cancer health care professionals perform. It is a privilege to be able to play a part in COSA's mission of improving cancer care and control and I very much look forward to working with my fellow COSA Board members to help realise COSA's objectives."




**COSA's
41** Annual
Scientific
Meeting

 Themes for
COSA's 41st ASM
will include:
cancer survivorship,
supportive care and
palliative care / lung
cancer / metastases

**2-4 December
2014**

 Melbourne Convention
and Exhibition Centre
Melbourne, Australia


Abstract Submission Guidelines

Online Abstract Submission

Please visit <http://www.cosa2014.org/the-conference/abstracts/> and follow the guidelines on how to successfully submit an abstract. An example is also provided of an exemplary abstract, and abstracts which would not meet the standard required for acceptance.

Abstract submission is online at:
<http://www.cosa2014.org/>

Abstract submissions close:
Wednesday 13 August 2014

Abstracts are invited to be submitted under one of the following categories:

Basic and Translational Research
Clinical Research
Education
Epidemiology
Health Services
Supportive Care *
Lung Cancer (Conference theme)
Survivorship (Conference theme)
Service Provision (poster only) **
Trials in Progress (poster only) **

* Supportive Care is a highly subscribed category. Submitters should consider the suitability of this category when submitting an abstract, as the potential for being awarded a presentation in the Supportive Care category is reduced.

** These abstract categories are for non-scientific abstracts. They do not need to follow the normal abstract format and are only considered for poster submission and are still eligible for poster awards.

Tom Reeve Award for Outstanding Contributions to Cancer Care

COSA is proud to announce the 2014 recipient of the Tom Reeve Award for Outstanding Contributions to Cancer Care, Professor John Zalcberg OAM.

Professor John Zalcberg was the Director, Division of Cancer Medicine, at the Peter MacCallum Cancer Centre in Melbourne, Australia for 17 years prior to recently taking up the position of Professor of Cancer Research in the School of Public Health and Preventative Medicine at Monash University.

After earning a Bachelor of Medicine and Bachelor of Surgery from the University of Melbourne and a PhD in cancer immunology, he served as Director of Medical Oncology at the Heidelberg Repatriation Hospital and as Director of Cancer Services at the Austin and Repatriation Medical Centre.

A founder of the Lorne Cancer Conference and the Australasian Gastrointestinal Trials Group (AGITG), he is immediate past Chair of

the Board of AGITG after serving in this role for over 15 years and a past Board Member of Cancer Trials Australia. He is the current Co-Chair of the Cancer Drugs Alliance and Interim Chair of the Australian Clinical Trials Alliance.

A past Board Member of the NSW Cancer Institute, past President of the Clinical Oncological Society of Australia, and a past Member of the Consultative Council of the Victorian Cancer Agency, he has received a Medal of the Order of Australia Award (OAM) and the 2011 Cancer Achievement Award from the Medical Oncology Group of Australia.

Professor Zalcberg's clinical research interests include gastrointestinal cancer and health care outcomes. He has published more than 230 articles in peer-reviewed journals. He was a Principal Investigator for the EORTC advanced GIST trial in Australia and continues an active involvement in trials in this disease as well as other GI cancers. He continues an active clinical practice in GI cancer.

As one of his referees stated in their nomination "I can think of no other Medical Oncologist or indeed anyone in the Cancer field in Australia who

is more deserving or who has contributed as much as Professor Zalcberg has over the last 30 years." They went on to sum up their nomination stating "Professor Zalcberg has managed to achieve all this and yet remains humble and unassuming and always acknowledges the input and contributions of others. He is a true leader and a wonderful man who I have the utmost respect for."

COSA encourages those attending its Annual Scientific Meeting to register for the conference dinner where Professor Zalcberg will deliver his oration and be presented with the Tom Reeve Award.



Professor John Zalcberg OAM

COSA Travel Grants

COSA is pleased to call for travel grant applications from financial Society members to attend the Annual Scientific Meeting (ASM) in Melbourne from 2-4 December 2014. Each grant will be up to the value of \$1,000.

COSA-IPSEN Travel Award

In 2014 IPSEN continues its tradition of sponsoring four COSA members with travel grants up to the value of \$1,100. Recipients will have their names published in the Marryalyan and in the IPSEN Affinity Newsletter that goes to health care professionals within Australia.



COSA Trainee Travel Grants

COSA trainee travel grants aim to assist oncology trainees in Medical, Surgical or Radiation to attend the ASM or the Trainee Weekend in Melbourne, 29-30 November 2014.

All travel grant applications close: Monday 18 August 2014

All funds awarded are to be used for expenses incurred in attending the ASM. Please note all recipients of travel grants will be reimbursed after the event.

Please refer to **www.cosa.org.au** for further information on all travel grants

2014 Queens Birthday Honours List

Congratulations to the following friends of COSA:

Dr John Scarlett OAM

For service to medicine, particularly in the field of haematology.

Professor Jeff Dunn AO

For distinguished service to medical administration through leadership roles with cancer control organisations, and to the promotion of innovative and integrated cancer care programs.

The Honourable Dr Hendy Cowan AO

For distinguished service to the Parliament of Western Australia, to tertiary education, agriculture and regional development, and through significant contributions to cancer control organisations.

Professor Graham Giles AM

For significant service to medicine, particularly through cancer epidemiology and public health research organisations, and as a mentor.

Dame Jessica Corner



Congratulations to Professor Jessica Corner who was appointed a Dame Commander of the Order of the British Empire (DBE) for services to healthcare research and education.

Jessica is well known to COSA members having presented at the COSA ASM 2011 in Perth and the Cancer Care Coordination Conference in Sydney in March 2014.

COSA Clinical Professional Days 2014

COSA is pleased to once again offer Clinical Professional Day grant funding. The aim of these grants is to support COSA Groups to conduct "professional day" meetings or educational sessions aimed at fostering professional development. Please visit the conference website to register for the events which are held as pre- or post-conference workshops on Monday 1 December or Friday 5 December 2014 at the COSA ASM in Melbourne www.cosa2014.org.

The successful recipients in 2014 are:

GROUP: Adolescent and Young Adult Cancers (AYA)
CHAIR: Wayne Nicholls
WORKSHOP: AYA Workshop
WHEN: Friday 5 December 2014

GROUP: Cancer Biology and Biobanking (in collaboration with RACP)
CHAIR: Nik Zeps
WORKSHOP: Next Generation Pathology: At the heart of cancer care and research
WHEN: Monday 1 December 2014

GROUP: Cancer Pharmacists
CHAIR: Gail Rowan
WORKSHOP: COSA Cancer Pharmacists Clinical Professional Development Workshop
WHEN: Monday 1 December 2014

GROUP: Nutrition
CHAIR: Judy Bauer
WORKSHOP: Targeting Malnutrition in the Cancer Setting - Strategies and Initiatives to Improve Outcomes
WHEN: Monday 1 December 2014

GROUP: Psycho-oncology (in collaboration with PoCoG)
CHAIR: Haryana Dhillon
WORKSHOP: What's new in Psycho-oncology?
WHEN: Monday 1 December 2014

GROUP: Familial Cancer (in collaboration with HGSA)
CHAIR: Nicola Poplawski
WORKSHOP: 2014 COSA-HGSA Familial Cancer Clinics Clinical Professional Day
WHEN: 12 August 2014 at the "Familial Aspects of Cancer: Research and Practice" meeting at the Mantra Resort Kingscliff NSW.
 Register at www.kconfab.org

Congratulations to the successful applicants.



**Clinical
Oncology
Society of
Australia**

The Federation
 Conference and
 Exhibition Centre
 Hotel Grand Chancellor
 Hobart

For more information
 please visit www.cosa.org.au
 or call us on (02) 8063 4100

SAVE **17-19**
 November 2015
 THE DATE
 COSA's **42nd** Annual
 Scientific Meeting

COSA Group Reports

Cancer Care Coordination Group

The report from the COSA Cancer Care Coordination Conference Constructing Cancer Across the Continuum held the 4-5 March 2014 is now available via the Cancer Care Coordination Group page on the COSA website www.cosa.org.au. It provides a detailed summary of the key concepts discussed over the two days and highlights important considerations for cancer care coordination into the future.

Over the past couple of months the Cancer Care Coordination Group has been focused on completing outstanding tasks arising from the Conference, finalising the position paper, and considering the subcommittee structure as a strategy to driving national priority activities for the Group in upcoming months. The Coordinator was published in June to inform the membership and our cancer care coordination colleagues about new and existing resources and educational opportunities available to everyone. The Cancer Care Coordinator Database has been updated and can be accessed by COSA members via the Group's page on the website. Thanks to everyone who contributed.

The Professional Development subcommittee is progressing well with the development of a webinar. Details about how you can participate will be communicated later in the year as the subcommittee refines the presentation focus. They will also explore the use of online forums available to members on the COSA website. These forums will be categorised into key topics for discussion, or members can initiate their own discussion. If you'd like to know more about using this platform effectively please contact

Kate Whittaker, Cancer Care Coordination
Project Coordinator
kate.whittaker@cancer.org.au

Professor Patsy Yates
Chair, Cancer Care Coordination Group
p.yates@qut.edu.au

Kate Whittaker
Project Coordinator, COSA
kate.whittaker@cancer.org.au

Clinical Trials & Research Professionals Group

Chair:

Hema Rajandran-Maurel, Sir Charles Gairdner Hospital Cancer Centre; Medical Oncology Clinical Trials Unit, Western Australia

Executive Committee:

Dianne Lindsay (Deputy Chair), Australia and New Zealand Breast Cancer Trials Group, Newcastle; Sally Dean, Calvary Mater, Newcastle (Secretary); Jill Davison, Peter MacCallum Cancer Centre, Melbourne; Anne Woollett, Barwon Health, Geelong; Annette Cubitt, Royal Brisbane & Women's Hospital, Brisbane.

It is hard to believe that the mid-year Marryalyan report is due. As we all ponder where that time went and how quickly the months fly by, I am pleased to be able to provide encouraging updates on behalf of the Clinical Trials and Research Professionals Group (CTRPG). Following on from the positive feedback our Group received following the Professional Development day held at last year's COSA ASM, we re-grouped and thought more about how best to serve our members and

provide further opportunities in the area of professional development in the next 12 months.

Our Executive Committee has discussed the possibility of trying a more interactive way of providing professional development opportunities, perhaps web-based systems; this could be in the form of a webinar for training days or an online chat option for members to interact with us through the COSA site. The CTRPG will keep all of our members updated on these ideas and developments over the coming months. We are encouraged to have the support of COSA with the acceptance of our 2014/2015 Group Activity plan.

The longer term plan and activities for the CTRPG is to bring together as many clinical trials professionals as possible as we work towards common goals in each of our clinical trial centres. The Group would like to facilitate training opportunities and increase our recognition as a professional body within the industry. We hope to do this by increasing our profile and our membership across Australia; we wish to see more members from more organisations and greater participation in our training days and events.

The Terms of Reference for the CTRPG Executive Committee have been updated this year and will be tabled at the August COSA Board meeting. Changes include the update to our Group's name. To keep our members informed the Terms of Reference also outlines the CTRPG's aims, which are to:

- promote and maintain the quality standards of clinical trial coordination in oncology research in Australia and New Zealand;
- respond to the dynamic needs of members by providing continuing education;
- provide a forum for discussion

and exchange of experiences and information;

- strengthen relationships across professional disciplines and with cooperative oncology groups; and
- foster research within the scope of clinical trials management.

Finally, a couple of positions have become vacant on the Executive Committee this year and we encourage nominations to join. A newsletter was recently circulated calling for nominations, if this sounds like you or you would like to learn more about the role of the Executive Committee please get in touch with any of the people named at the beginning of this report. Membership of the CTRPG is open to individuals involved in clinical cancer research including but not limited to clinical trial coordinators, research nurses, clinical research managers, data managers, clinical research associates, and health information managers involved in research.

The CTRPG is committed to achieving and promoting excellence in clinical cancer research by supporting research professionals through education, information, leadership, and networking opportunities. Thank you again to all of our members for their continuing support.

Hema Rajandran-Maurel
Chair, Clinical Trials & Research
Professionals Group

Hema.Rajandran-Maurel@health.wa.gov.au

Familial Cancer Group

The 2014 COSA/Human Genetics Society of Australia (HGSA) Familial Cancer Clinics Clinical Professional Day will be held Tuesday 12 August 2014, at the Mantra Resort, Kingscliff, NSW. This annual meeting is very clinically orientated and will give delegates clear ideas and understanding of how they might apply up-to-date information about familial cancer in a clinic setting. The meeting is relevant to all

professionals working in oncology.

The programme for 2014 is:

1. Genomics – what can we translate to the clinic?
2. BRCA-associated prostate cancer – the clinical issues
3. Rare Cancers (Fanconi anaemia, familial leukaemia and a update on new rare cancer genes)
4. Germline CDH1 mutations: managing gastric and breast cancer risk

If you come to the Familial Cancer Clinics Clinical Professional Day, you may want to stay on for the annual “Familial Aspects of Cancer: Research and Practice” meeting, the annual combined clinical and scientific meeting of kConFab, the Australasian Colorectal Cancer Family Study, the Australian Breast Cancer Family Study, the Australian Pancreatic Genome Initiative and the International Sarcoma Kindred Study (August 13-15, also in Kingscliff). This meeting has attracted a number of high quality international speakers, and most are well recognised as leaders in their fields. Information about both meetings is available at <http://www.kconfab.org/Index.shtml>

For those of you interested in familial ovarian cancer, there is emerging evidence that the inhibin/activin pathway has a role in young onset serous adenocarcinoma of the ovary. Rare germline mutations have been identified in the INHA and INHBA genes. Further research is needed before the full clinical significance and frequency of mutations in this pathway is understood (see Tournier et al Germline Mutations of Inhibins in Early-Onset Ovarian Epithelial Tumors, Human Mutation 2014;35(3):294-7).

The protein BRG1 is encoded by the SMARCA4 gene and is part of the SWI/SNF complex – a complex that has an important role in the control of gene expression via chromatin remodelling. Somatic (tumour) mutations have previously been associated with a range of different cancers including medulloblastoma, lung and pancreatic cancer. Germline (heritable) mutations

have previously been described in the rare rhabdoid tumor predisposition syndrome type 2. A series of papers in the May 2014 issue of Nature Genetics (Jelincic et al p424-426, Ramos et al p427-429 and Witkowski et al p438-443) highlight the importance of germline mutations in the SMARCA4 gene in small-cell carcinoma of the ovary, hypercalcaemic type (SCCOTH), an aggressive ovarian cancer subtype that affects young women (mean age 23 years) and is refractory to standard chemotherapy with agents like cisplatin or cyclophosphamide. The groups also showed SMARCA4 mutated SCCOTH tumour tissue shows immunohistochemical loss of BRG1, confirming that immunohistochemistry can be used to target genetic testing to women likely to have a mutation. All three research groups are hoping to develop targeted therapies based on this new genetic knowledge. If effective agents are identified this could have therapeutic implications for a wide range of cancer types. Watch this space!

Nicola Poplawski
Chair, Familial Cancer Group

Free and complete online access to
Asia-Pacific Journal of
Clinical Oncology
for COSA members

COSA members can access your official journal for FREE through the member's section of the COSA website.

www.cosa.org.au

Simply log-in using your member number and password, and follow the links for full access to the Journal through Blackwell Synergy.

- Full search capabilities
- Free email table-of-contents alerts
- OnlineEarly alerts
- All available in email or RSS and Atom formats

Discover more with Wiley-Blackwell.

 **WILEY-
BLACKWELL**

Geriatric Oncology Group

By the time of publication the COSA Geriatric Oncology Group would have held a pre-congress workshop to the Cancer Nurses Society of Australia (CNSA) Winter Congress. I will provide an overview of the workshop in the next edition of the Marryalyan and shortly, you will be able to access a full report on the discussion and outcomes via the COSA website. A huge thank you to Jane Phillips for facilitating this workshop and her team for developing a comprehensive program to support nurse – led strategies to identify the needs of the older cancer patient.

Tim To and Jane Philips have been leading a group of COSA Geriatric Oncology Group members in developing research activities and protocol to inform the role of geriatric assessment in oncological practice. The group has met three times since the beginning of year and are close to finalising their survey and semi-structured interview questions and research protocol. This collaborative work will put forward important research to guide future practice including the needs, and delivery for geriatric assessment for general oncologists. I will be able to report further on this progress later in the year, however, this is a very exciting scoping exercise to assist a strategy for the future direction for the COSA Geriatric Oncology Group.

I have had the honour of being an invited speaker at the 50th ASCO meeting in Chicago and at the next SIOG Asia Pacific (APAC) meeting in Singapore. The ASCO session was entitled “Developing a geriatric oncology presence at your academic institution or community-based practice” during which I was able to inform attendees of the geriatric oncology initiatives in Australia and around the world. We are recognised as being a country with a small but established geriatric oncology presence and COSA is the key to the

viability of this effort. I will continue to reinforce the important work of the COSA group at the SIOG APAC meeting in July and hope that some of our members will attend this meeting. I look forward to presenting the work of the COSA group at such meetings in the future.

Christopher Steer
Chair, Geriatric Oncology Group
Christopher.Steer@bordermedonc.com.au

Neuro- Oncology Group

Brain Cancer Action Week was held across different Australian states Sunday 27 April - Saturday 3 May 2014 with many key events and initiatives. A list of some initiatives can be found here:

<http://braincanceraction.com.au/2014/04/10/brain-cancer-action-week-2014/>

A Brain Tumour Support and Education Forum was held in Sydney on 1 May, and was linked via live webcast to consumers and health professionals in both SA and WA. Videos of various presentations from the Forum can be found here:

<http://www.curebraincancer.org.au/news/1060/brain-tumour-support-and-education-forum>

Selected upcoming events in 2014:

- **Brain Tumour Clinical Education Day - A forum for health professionals**

Friday June 27, 2014, hosted by Cancer Council Qld, Brisbane

For more information:
www.cancerqld.org.au/bted

- **COGNO** will hold its **7th Annual Scientific Meeting**, from 24 – 25 October 2014 in Melbourne.

COGNO is pleased to host two esteemed international guest speakers: Professor Lisa DeAngelis, Department of Neurology, Memorial Sloan-Kettering Cancer Center, USA; and Professor Minesh Mehta, Radiation Oncologist from the Maryland Proton Treatment Center, Maryland, USA; as well as a number of well-known Australian experts as part of the COGNO program.

For more information:
<http://www.cogno.org.au/content.aspx?page=cognoasm-speakers>.

- **The Society for Neuro-Oncology (SNO)** is holding its **Annual Scientific Meeting** 13-16 November 2014, South Beach, Miami, Florida.

For more information:
<http://www.soc-neuro-onc.org/2014-annual-meeting/>.

Please contact Dr Koh (eng-siew.koh@sswahs.nsw.gov.au) if you have suggestions regarding any aspect of COSA Neuro-Oncology.

Best wishes,

Dr Eng-Siew Koh
Chair, Neuro-Oncology Group

Associate Professor Kate Drummond
Deputy Chair, Neuro-Oncology Group

Australian Psycho-Oncology Society, the COSA Psycho- Oncology Group

Psycho-Oncology Professional Day – a collaboration between COSA, OZPOS & POCOG

COSA and POCOG have once again supported our application for a Clinical Professional Day. This year the Professional Day will in fact be half a day, jam-packed

with oral research presentations (selected from abstracts submitted to COSA but not selected for oral presentation), an update on progress with the clinical pathways for distress screening and a closing plenary addressing the changing face of advanced cancer – living with a chronic life-limiting illness. The morning will be devoted to a multidisciplinary session where the COSA Survivorship Working Group will propose a Model of Survivorship Care for the Australian context. We are looking forward catching up with all of you there.

COSA ASM 2014

Don't forget to submit your abstracts and contribute to the exciting COSA program. The Annual Scientific Meeting, back to back with UICC, will focus on cancer survivorship and lung cancer. There are excellent multidisciplinary plenaries and sessions planned. It is shaping up to be a vibrant discussion of great interest to members of the psycho-oncology community.

Psycho-Oncology Awards 2014

Nominations are now open for these awards. Please carefully consider whether you are prepared to nominate one of your peers, a mentor, supervisor, or someone who has influenced your career for either the:

- COSA Psycho-Oncology Award; or,
- New Investigator in Psycho-Oncology Award.

This is a great opportunity to celebrate the strength and diversity of psycho-oncology research and practice in Australia.

Haryana Dhillon
Chair, Australian Psycho-Oncology Society

COSA Psycho- Oncology Awards 2014

COSA is once again pleased to announce the COSA Psycho-Oncology Awards for 2014.

Nominations are now open for these two awards:

• COSA Australian Psycho-Oncology Award

This Award recognises the highest level of contribution to psycho-oncology from amongst the membership of COSA, OZPOS and PoCoG.

• COSA New Investigator in Psycho-Oncology Award

The New Investigator Award recognises an early career investigator for outstanding research contributions in the field of psycho-oncology.

For more information on either award please visit www.cosa.org.au/grants-awards/cosa-psycho-oncology-awards.aspx.

Previous recipients of these exciting awards are Professor Afaf Girgis, the Australian Psycho-Oncology Award and Dr Haryana Dhillon recognised with the New Investigator Award.

Nominations close
Friday 5 September 2014.

Please forward nominations to
cosa@cancer.org.au.

Regional & Rural Group

The COSA Regional and Rural Group is a multidisciplinary group focused on the unique issues facing cancer service delivery outside metropolitan areas. Our goals are to work at highlighting the deficiencies in service delivery and to enhance the equity of access to current best practice care, cancer services and clinical trials.

In June 2013 a new Regional and Rural Executive Committee was formed following a call for nominations from COSA members. Members of the new Executive Committee are directly involved in the delivery of care, working in regional and rural areas or are responsible for regional services. The Committee plan to meet bi-monthly by teleconference and face to face once a year.

The Executive Committee have identified several key priorities going forward. The first priority is to establish a formal network for directors and clinical leads of the Regional Cancer Centres. The aim of the network is to facilitate communication and collaboration between Regional Cancer Centres in order to plan and advocate for improvements in cancer services for regional and rural patients. A face to face meeting of the network is currently being planned for late October.

Other priorities which have been identified include the development of telehealth guidelines specifically for oncology and the development of a framework for AYA patients in Regional and Rural areas. The Committee are also planning to facilitate the collation of information for Indigenous patients which can then be made available on the COSA website.

If you would like more information about any of these projects, please don't hesitate to contact me or Chantal Gebbie, COSA project coordinator
chantal.gebbie@cancer.org.au.

Sabe Sabesan
Chair, Regional and Rural Group
sabe.sabesan@health.qld.gov.au

Social Work Group

The OSWA conference in Adelaide is rapidly approaching! It's not too late to register for any of the days: Thursday 31 July - Saturday 2 August. The theme is *The Fabric of Modern Family: Working with Life, Loss and Love*. Our international Key Note speaker is Shirley Otis Green from City of Hope Medical Center, USA. The hard-working South Australian OSWA members have put together an outstanding program, with something of interest for everyone; and of course the opportunities to network and socialise with colleagues whom we rarely see is inestimable.

Check out the conference program and lots of other great features on our revamped web site, www.oswa.net.au. OSWA Membership for 2014 is now due and applications for new and renewing membership are very easy to complete online.

The next COSA Council meeting is on Friday 29 August, and I hope to be able to report in the next edition of *Marryalan* the developments in negotiations between COSA and OSWA to strengthen our collaborative partnership.

Kim Hobbs
Chair, Social Work Group

Survivorship Group

Since our last report we have welcomed Hayley Griffith, COSA Project Officer, to our team. Hayley is providing support for the activities we are undertaking. I'd like to extend my sincere thanks to Chantal Gebbie who ably supported our group through its first year.

Models of Survivorship Care Working Group

Work on an Australian model of care continues, ably supported by Hayley Griffith. There will be a workshop held on 1 December, prior to the start of the COSA ASM. If you have an interest in models of survivorship care, please register for this workshop and join us. The aim is to introduce the model and to use the opportunity to plan further work priorities to support implementation of survivorship care, key issues already identified include workforce availability and integration across primary care, community organisations and cancer centres.

COSA ASM 2014

I hope you are all thinking about abstracts for submission to this year's conference. With a main theme of Survivorship, it is going to be a really exciting event for our Group. There will be many opportunities for interaction across our very diverse Group. I'm looking forward to seeing everyone in Melbourne.

Haryana Dhillon
Acting Chair, Survivorship Group

Urologic Oncology Group

Many members of the COSA Urologic Oncology Group will still be coming to terms with remarkable data presented at ASCO in June. The CHAARTED E3804 results were presented by Chris Sweeney at the plenary session and showed that the addition of six cycles of docetaxel to androgen deprivation in men with hormone-naïve prostate cancer led to a very substantial improvement in survival: 13.6 months for the study overall (57.6 months median overall survival compared to 44.0 months; hazard ratio 0.61), and 17 months improvement in the subgroup

with high volume metastatic disease (49.2 vs 32.2 months, HR 0.60). These remarkable results represent the most substantial improvement in survival for men with metastatic prostate cancer since the introduction of androgen deprivation therapy itself. We can expect changes in clinical practice as a result. Clinicians should note however that docetaxel is not currently reimbursed for this indication under the PBS; we hope that this will be changed in the near future. It is remarkable to consider that the original pivotal trials of docetaxel in castrate-resistant prostate cancer were published only 10 years ago. So much is changing so rapidly in our field.

Other key presentations at ASCO in the genitourinary stream continued the theme of cancer immunotherapy. Everyone is a believer now but as a card-carrying immunotherapist I remember it was not so long ago that we were seen as the poor deluded unfortunates of the cancer research community! Presentations at ASCO demonstrated activity of the horribly-named "immune checkpoint" drugs in a range of diseases, including renal cell carcinoma and urothelial cancer. This area will continue to develop rapidly over the next few years and we look forward to new trials and new therapeutic options for these patients.

The Group itself otherwise has been fairly quiet. I encourage all members to consider using the COSA Urologic Oncology Group Forum, available via secure login on the COSA web site www.cosa.org.au. Go to Groups, Urologic Oncology, Discussion, and you will see options for posting discussions.

My thanks as always go to the other members of the Urologic Oncology Group Executive (Shomik Sengupta and Scott Williams), COSA Executive Officer Marie Malica, COSA Board and COSA Council, for their great support.

Ian Davis
*Chair, COSA Urologic Oncology Group
Director, COSA Board*

COSA Membership

COSA Membership renewals NOW OPEN!

Have you renewed your COSA membership yet? Don't forget the price of a COSA membership is the difference between the member rate and non-member rate to register for the Annual Scientific Meeting – why wouldn't you renew or join?

To renew your membership please log onto the COSA website **www.cosa.org.au** and you will be directed straight to the membership renewal page.

The membership categories and prices are listed below:

- | | |
|--------------------------------|-----------------------|
| • COSA – medical (1 year) | \$170 |
| • COSA – medical (2 years) | \$325 |
| • COSA – non medical (1 year) | \$110 |
| • COSA – non medical (2 years) | \$210 |
| • COSA Student member | (1 year)
no charge |
| • COSA Retiree member (1 year) | \$55 |

COSA welcomes Affiliated Organisations, which brings many opportunities one of which is discounted COSA membership to members of Affiliated Organisations. Membership costs are listed below:

- | | |
|--|-------|
| • COSA affiliate members – medical (1 year) | \$145 |
| • COSA affiliate members – medical (2 years) | \$290 |
| • COSA affiliate members non-medical (1 year) | \$100 |
| • COSA affiliate members non-medical (2 years) | \$190 |

For more information regarding Affiliated Organisation Memberships please contact COSA
cosa@cancer.org.au

If you have any queries or concerns regarding your membership, please do not hesitate to contact the COSA office on 02 8063 4100 or email
cosa@cancer.org.au



PSA 2014
50th Annual Scientific Conference

REGISTER ONLINE NOW!
<http://tinyurl.com/PSADarwin>
Email psa@surgeons.org to request a copy of the Provisional Program.

Photo credit: Tourism NT

PSA Scientific Program
Thursday 21 - Friday 22 August

Trauma Symposium
Saturday 23 August


FURTHER INFORMATION
RACS Conferences and Events Management
Royal Australasian College of Surgeons
250-290 Spring Street, EAST MELBOURNE VIC 3002
T: +61 3 9249 1139
E: psa@surgeons.org

**21-23
AUGUST**
D A R W I N
C O N V E N T I O N
C E N T R E , D A R W I N ,
N O R T H E R N
T E R R I T O R Y

Did you know COSA is on social media?



Please follow us on Twitter
<https://twitter.com/COSAoncology>



Like our Facebook Page
<https://www.facebook.com/pages/COSA-Clinical-Oncology-Society-of-Australia/172334056270046?ref=hl>



**Clinical
Oncology
Society of
Australia**

TRAINEES WEEKEND

**Everything you need to know
about lung cancer**

DATES

Saturday 29 November and
Sunday 30 November 2014
(preceding the COSA ASM)

VENUE

Melbourne Convention and
Exhibition Centre
1 Convention Centre Place
South Wharf VIC 3006



REGISTRATION

2 day

\$350 medical / \$150 allied health

1 day

\$200 medical / \$100 allied health

An intensive 2-day course for advanced trainees in surgery, medical and radiation oncology; as well as junior medical staff and allied health professionals including nurses.

DISCOUNTS

Discounts may apply for delegates also attending the COSA ASM, 2-4 December 2014 at the Melbourne Convention and Exhibition Centre

Trainee Travel Grants available, visit www.cosa.org.au for more information.

PROGRAM HIGHLIGHTS

- Concentrated program on lung cancer
- Function of the MDT
- Controversies in lung cancer
- Meet the experts
- Seminal papers
- Pathology and staging of lung cancer
- Principles of surgery, radiotherapy and chemotherapy



This meeting is supported by an unrestricted educational grant from Roche Products Pty Limited.

For more information and to register visit
www.cosa2014.org

COSA Affiliated Organisation Reports

Australasian Gastro-Intestinal Trials Group



AGITG is committed to supporting new research through awards, grants, courses and conference organisation and participation. Here are some examples of our recent and forthcoming efforts...

Bringing together leading GI cancer researchers

World leaders in gastro-intestinal (GI) research will gather in Brisbane from 20-22 August for the AGITG's **16th Annual Scientific Meeting**. More at agitg.asnevents.com.au/

The meeting will feature international presentations on key research, updates on AGITG clinical trials, a New Concepts Symposium, and interactive workshops.

The day before the opening of the Annual Scientific Meeting, on 19 August, AGITG and **Australasian Pancreatic Club (APC)** will host a half-day workshop on **Pancreatic Cancer - to foster collaboration and develop new research**.

The workshop at the Sofitel, Brisbane Central will be open to **scientists, clinicians, pharmaceutical companies, consumers and anyone with a strong interest in Pancreas Cancer Research**. More on the workshop at agitg.org.au.

Engaging with the community for better understanding

Another satellite event of the Annual Scientific Meeting will be an Engage Community Forum, to be held at the Sofitel, Brisbane Central on the evening of 19 August. The forum will bring people

living with GI cancer and their supporters together with cancer service providers, researchers and clinicians. The forum will highlight opportunities to learn about latest research, treatment and connections to support networks and services.

Further *Engage Forums* are planned for Perth, Canberra and Sydney later in the year. More at gicancer.org.au/engage/

New chair for AGITG

At the 2014 AGITG Annual General Meeting held in Sydney on 16 May 2014, Professor John Zalberg OAM retired as AGITG Chairman and from the Board of Directors. Professor Zalberg has contributed immensely to the success of the organisation over many years and will remain actively involved in the Group.



The new AGITG Chairman is Associate Professor Tim Price. He has been a member of the Board of Directors and Scientific Advisory Committee since 2004

and has served in numerous leadership positions including Principal Investigator on the PETACC-6 Clinical Trial, Annual Scientific Meeting (ASM) Convenor (2008-2012), Chair of the Upper GI Working Party (2011-2014) and Company Secretary (2004-2014).

Said Professor Zalberg: "Tim is a highly respected member of the Board and everyone is thrilled at his appointment. He

continually demonstrates his commitment to GI cancer research and his outstanding leadership qualities in the many roles he holds. There's no doubt Tim is an ideal person to lead the Board as the AGITG continues to grow from strength to strength".



CRC Preceptorship, Sydney, July 2013

Colorectal cancer course

Participants from around Australia were sponsored by AGITG to attend the second annual Preceptorship in Colorectal Cancer, in Sydney on 25-26 July, 2013.

The two-day intensive learning course featured a comprehensive review of literature to allow participants to better understand the evolution of treatment for CRC in the adjuvant and metastatic settings, in the context of current treatment.

The course especially targeted trainees and junior consultants in Medical, Radiation and Surgical Oncology. CRC topics covered included basic biology and translational science, current therapies, adjuvant therapy, treatment paradigms, and treatment pathways involving liver resection to achieve cure.

Making a mark at ASCO

AGITG also continues to make hefty contributions to the worldwide GI cancer research effort. Eight AGITG clinical trial papers have featured at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from 30 May to 3 June 2014.

The meeting brought together more than 25,000 oncology professionals from a broad range of specialties to explore the theme of "Science and Society."

ASCO promotes and provides for lifelong learning for oncology professionals; cancer research; an improved environment for oncology practice; access to quality cancer care; a global network of oncology expertise; and educated and informed patients with cancer.

Details of the AGITG papers presented at the conference are available online at agitg.org.au/agitg-at-asco/

GI cancer news online

The AGITG website at agitg.org.au features latest news from clinical trials and other GI cancer research, background, and updates on conferences and other events.

Associate Professor Tim Price
Chairman, Australasian Gastro-
Intestinal Trials Group

Australasian Leukaemia and Lymphoma Group



The ALLG is unique in having two Scientific Meetings each year, held in May and November, and rotating through Sydney, Melbourne, Adelaide and Brisbane. Recognising the central importance of the sites in the conduct of trials, they always include two full days of activities for data managers/research nurses.

The first day is a special haematology educational day. At the May meeting, the focus was Acute Myeloid Leukaemia, with presentations given by leading haematologists Andrew Wei (Alfred Hospital), David Westerman (Peter MacCallum Cancer Centre), Melita Kenealy (Cabrini Hospital) and David Ritchie (Royal Melbourne Hospital). These intensive full day courses provide site staff with unparalleled training in the knowledge necessary to run our highly technical haematology trials. Support from Roche Australia allows us to provide this educational day at no cost to participants.

The second day is devoted to selected ALLG trials and short educational presentations. A highlight at the May Data Managers/Research Nurses Day was the first presentation of a newly established award, the Janey Stone Perpetual Award.

The creation of this Award was part of the 40th anniversary commemoration of the group in 2013 and it honours Janey's

advocacy for the professional role of trial coordinators and site staff.


The Award was established in recognition of the fact that trial coordinators, data managers and research nurses play a pivotal role in the conduct of ALLG trials and yet have only very limited access to funding to support projects and professional development. It is named for Janey Stone who was a Trial Centre Trial Coordinator and Executive Officer of the ALLG. For over 25 years she promoted recognition of the data managers/research nurses within the ALLG clinical research process, instigated training and travel opportunities and conducted research projects resulting in conference presentations and publications.

The aims of the award include

- Promotion of professional development and skills
- Encouragement of the study and improvement of trial processes
- Allow the ALLG to draw upon the wealth of knowledge, skills, experience and expertise found amongst trial coordinators, data managers and research nurses for the benefit of the ALLG trials program and ultimately patients with haematological malignancies.

The award, worth \$2000, is open to all Associate Members of the ALLG and is offered in two categories – a travel grant or to undertake a project.

The first recipient was Naomi Sprigg from the Royal Melbourne Hospital. As the Haematology Tissue Bank Coordinator, she carries out a very important role in assisting collection, processing, transport and storage of blood and bone marrow samples for ALLG trials and the ALLG Tissue Bank. The funding assisted her to attend and present a poster at the International Society for Biological and Environmental Repositories (ISBER) Conference in Orlando Florida in May.



In her application Naomi commented: "Attending ISBER will enable me to ensure I am up to date with national and international trends in human specimen repositories, including approaches to tissue banking, ethics and consent process."

ALLG trials have associated laboratory collaborative studies, and in addition the ALLG Tissue Bank is a nationally based repository of samples from both trial and non-trial patients. As such it is an incomparable resource for future translational research. Naomi will give a presentation at the November Data Managers/Research Nurses Day. She will also have an ongoing role in assisting the ALLG with sample coordination issues and the Tissue Bank, based on her site experience and skills and knowledge learnt at the conference.

The Janey Stone Perpetual Award will be offered annually. Anyone seeking further information should contact the ALLG Operations Unit at

Dilupa.Uduwela@petermac.org



Left to right: Janey Stone (ALLG), Naomi Sprigg (Royal Melbourne Hospital), Delaine Smith (ALLG CEO)

Mark Hertzberg
Chair of the ALLG Scientific Advisory Committee

Australia New Zealand Gynaecological Oncology Group

2013 was a stellar year for ANZGOG. Highlights included our highest recorded clinical trial recruitment numbers (864 patients recruited in 2013) and an all-time highest open trials portfolio, with 8 trials in operation. Furthermore, from a financial perspective as well, 2013 was our best year with a significant contribution from a bequest to ANZGOG research. Sowing from this success ANZGOG ploughed into 2014 with vigour and determination.

The first half of 2014 has been tremendously busy, productive and stimulating. We had a very successful combined Annual Scientific Meeting with the Australian Society of Gynaecological Oncologists (ASGO) at the Hyatt Hotel in Canberra. The theme of the conference was 'Progress through collaboration and innovation'. The 227 delegates from across Australia and New Zealand who attended the conference had plenty of opportunity for debate, discussion and reflection. This year we had three leading international keynote speakers: Professor Lynette Denny, Gynaecological Oncologist and President of IGCS from the Groote Schuur Hospital, South Africa; Professor Jonathan Ledermann, Medical Oncologist from UCL Cancer Institute, University College London, UK and Associate Professor Akila Viswanathan, Radiation Oncologist from Harvard Medical School, USA. They shared their expertise, knowledge and insight on current gynaecological cancer research, on obesity and its implications for cancer treatments and the inequities in care of women with gynaecological malignancies.



Professor Jonathan Ledermann UK



Professor Lynette Denny, President IGCS (International Gynaecologic Cancer Society)

Along with the thought-provoking scientific sessions at the conference, ANZGOG members also coordinated and held 3 Tumour Type Working Group meetings with involvement from 25 members, a 2-part Brachytherapy workshop, a well-attended Study Coordinator Workshop on 'Audit Readiness: building in quality through harmonisation and process improvement' and a Clinical Research Ideas Starter Workshop. The conference was also the platform for 19 Abstract presentations by ANZGOG members and 6 new Trial Concept presentations. The ANZGOG Research Advisory Committee was especially interested in the trial concept presentations for deliberation on potential future ANZGOG trials.



Dr Alison Brand, ANZGOG Chair speaking with members

Our fundraising and public awareness campaign has also made amazing strides this year. ANZGOG partnered with the Big Film Festival in Sydney and hosted the movie 'No Evidence of Disease' (N.E.D.). This award winning movie is about a group of musicians who are also gynaecological oncologists in the USA and documents their music, their lives and their patients. The charity night hosted over 150 guests supporting ANZGOG and our mission. It was an extremely thrilling night for us.

We have excellent success with philanthropic and government grants with support for our New Research Fund and from BUPA funding for the MOST Study. ANZGOG was also very fortunate to have been awarded a 3 year NHMRC Grant for the PARAGON Trial. This is a huge success for ANZGOG.

I look forward to continuing our collaborative work in improving the life of women with gynaecological cancer through research and reporting on many more successes this coming year.

As always thanks to all our members for your support.

Alison Brand
*Chair, Australia New Zealand
Gynaecological Oncology Group*

Australian and New Zealand Urogenital and Prostate Cancer Trials Group



ANZUP Cancer Trials Group continues to be very active. Several new trials have been initiated this year including two large international studies in prostate cancer. Our membership continues to grow and we encourage new members to join: this will also give you a 10% discount on your COSA membership!

The ANZUP Annual Scientific Meeting was held in Melbourne on 13-15 July 2014. Once again there was a packed scientific program, with a galaxy of stars from Australia and New Zealand presenting on all aspects of genitourinary cancers. Our international speakers included Rob

Bristow, radiation oncologist and clinician-scientist from Toronto; Eric Klein, Professor of Urology at Cleveland Clinic; Christian Kollmansberger, medical oncologist at British Columbia Cancer Agency, Vancouver; and Theresa Wiseman, nurse and health service researcher at Royal Marsden. The theme of the meeting was, "From ideas to outcomes: patient focused research," reflecting ANZUP's commitment to performing research that will lead to tangible patient benefits and also to fostering research all the way from the initial concept through to completion and implementation of the outcomes. The content of the meeting reflected this theme all the way through, extending to the MDT Masterclass "Challenging Cases in Uro-Oncology" (formerly the Trainees Day) held on Sunday 13 July. A very successful Community Engagement Forum was held on the same day, open to the public and free of charge. Our Consumer Advisory Panel participated in an Education Session, and our Scientific Advisory Committee held a meeting that was open to all ANZUP members to attend. Thanks of course to our meeting sponsors: Platinum Sponsors Janssen and Prostate Cancer Foundation of Australia; Gold Sponsors Astellas, Pfizer Oncology, Sanofi, Tolmar Australia; Silver Sponsors Amgen Oncology, AstraZeneca Oncology, Bayer, Ipsen, GSK; and Bronze Sponsor Ferring Pharmaceuticals.

I would also like to thank and acknowledge the following sponsors for their additional support: Pfizer – Evening Symposium; Bayer – ANZUP/Bayer Travel Fellowships; Janssen – MDT Masterclass; Astellas – Best of the Best Awards; Victorian Government – Mobile App; and Ipsen – AV.

Once again the ASM was a huge success and we are already looking forward to the 2015 meeting.

As always there is a cast of thousands to thank for the success of these meetings but I would particularly like to acknowledge the ASM convening committee led by David Pook and comprising Belinda Jago, Shankar Siva, Henry Woo, Jeremy

Grummet, Ben Tran, Andrew Weickhardt, Carmel Pezaro, Kathryn Schubach, Emma Beardsley, Amy Hayden and Shomik Sengupta for their tireless efforts in developing an exceptional scientific program. Thank you also to our subcommittee Chairs for providing invaluable advice and support. I am very grateful to our MDT Masterclass convenor Andrew Weickhardt and to all the panel members and participants. Particular thanks go to our Executive Officer Marg McJannett, our project officer Yi Feng, our Marketing and Communication manager Liz Thorp, and our new Internal Communications and Project Manager Jenni Beattie, who commenced with ANZUP in June.

ANZUP is also pleased to announce the launch of our inaugural "Below the Belt Pedalthon" to be held at Sydney Motor Sport, Eastern Creek on Tuesday 16 September.



THE ULTIMATE TEAM CHALLENGE

RIDING 4 FOUR HOURS TO DEFEAT 4 BELOW THE BELT CANCERS

Whether you are the devoted cyclist looking for a challenge or the weekend cyclist looking to help a great cause while staying fit, help us Defeat 4 Below the Belt Cancers. If you are interested please contact ANZUP's marketing and communications manager **liz.thorp@anzup.org.au** for more details on how to get involved or support this event.

Don't forget membership of ANZUP is free, and ANZUP members receive a discount

on COSA membership and COSA ASM registration. Why would you not be a member of both? More details are available through the web site at www.anzup.org.au. Please especially encourage your junior colleagues to join and contribute to both ANZUP and to COSA.

Ian Davis

Chair, ANZUP Cancer Trials Group

Cancer Nurses Society of Australia



The 17th CNSA Winter Congress 24th -26th July, hosted in Melbourne attracted more than 500 delegates from around Australia. Themed with Leading in a Time of Change, international key note speaker Dr Theresa Wiseman shared her expertise and knowledge as the Lead for Health Service Research, Nursing, Rehabilitation and Quality, at The Royal Marsden NHS Foundation Trust, London UK and lead investigator on the internationally acclaimed work on Evidence Based Co-Design, an innovative and uniquely patient-centred approach to improving UK health services provision.

Delegates were also exposed to a number of national speakers including Associate Professor Gail Garvey, a Kamilaroi woman from New South Wales and Senior Research Fellow at Menzies School of Health Research, who articulated the needs of indigenous cancer patients through her work in Indigenous education and health research and Professor Grant McArthur, a Fellow of the Royal Australasian College of Physicians whose research interests include

clinical trials of targeted therapeutics, molecular haematology, melanoma, cell cycle control, differentiation, and functional imaging. Professor Claire Rickard, from the NHMRC Centre for Research Excellence in Nursing at the Griffith Health Institute, Griffith University gave her insights into current evidence based practice on appropriate use of intravascular access device for treatment. For a wrap up of all that was the 17th CNSA Winter Congress please visit <http://www.cnsawintercongress.com.au/>

Nominations for 2015 vacancies to the National Executive were open in May and it was pleasing to see members from the states step up to represent CNSA. Two new executive members will commence in January 2015, Lucy Patton in WA (Sam Gibson will complete her term) and Nicole Loft (current ex- officio member) will formally take up her term. Vacancy exists for representation in the ACT and ex officio representation will be considered from current members.

Expressions of interest were also sought for the CNSA Research Committee, with 11 nominations for six positions received. This committee determines recipients of the CNSA research grant applications, reviews applications to survey the membership and the development of a CNSA research agenda, bringing our membership together in a range of collaborative opportunities. Details of the expanded committee can be found at <https://www.cnsa.org.au>

The South Australian Regional Group, who reformed their committee in late 2013, will host its first networking and education event in Adelaide this August. To start their new initiative, CNSA Past President and COSA President Elect Associate Professor Mei Krishnasamy, will present her esteemed Robert Tiffany Oration to the local members. The committee has worked extremely hard to engage local cancer nurses, increase membership and hopes to provide a range of local initiatives throughout the year and should be congratulated.

For further information about the CNSA local activities please see the CNSA website or contact your state representative.

Sandy McKiernan

CNSA President

Cooperative Trials Group for Neuro-Oncology

COGNO held a very successful Ideas Generation Workshop in May, co-chaired by Dr Mustafa Khasraw and Dr Zarnie Lwin. Participants presented a range of interesting ideas and concepts. Work is now under way to further develop a number of these.

COGNO will hold its **7th Annual Scientific Meeting 24-25 October 2014, at The Langham in Melbourne**. All COSA members are invited to attend. Visit www.cogno.org.au/content.aspx?page=cognoasm-program to view the program.

- Online registration is now open. Register at www.cogno.org.au/content.aspx?page=cognoasm-reg
- **Call for Abstracts:** Members of the neuro-oncology community and related professions are invited to submit abstracts for presentation as part of the COGNO 2014 Annual Scientific Meeting. Abstracts for both poster and oral presentations including original work in clinical, translational and allied health research will be considered. There will be prizes offered to the two best abstracts. Visit www.cogno.org.au/content.aspx?page=cognoasm-abstracts for further information
- **COGNO/Cancer Institute NSW Travel Grants for NSW rural/**

regional trainees: COGNO and Cancer Institute NSW are pleased to announce the opportunity for NSW rural/regional trainees to apply for a 2014 travel grant to attend the COGNO Annual Scientific Meeting. For further information on travel grants see www.cogno.org.au/content.aspx?page=cognoasm-grants.

• **Important dates:**

Registration Opens **30 May 2014**

Abstract Submission Opens **30 May 2014**

COGNO/CINSW Travel Grants for NSW rural/regional trainees Opens **30 May 2014**

Early Bird Registration Closes **1 Aug 2014**

Abstract Submission Deadline **1 Aug 2014**

COGNO/CINSW Travel Grants for NSW rural/regional trainees Submission Deadline **5 Sep 2014**

Abstract Presenters Notified **Sep 2014**

COGNO/CINSW Travel Grants for NSW rural/regional trainees Recipients Notified **Sep 2014**

Online Registration Closes **10 Oct 2014**

Mark Rosenthal
Chair, Cooperative Trials Group for Neuro-Oncology

NHMRC Clinical Trials Centre



COOPERATIVE TRIALS GROUP FOR NEURO-ONCOLOGY

The achievement of better health outcomes for patients and those affected by brain tumours through clinical trials research

www.cogno.org.au

email: cogno@cogno.org.au | tel: 02.9562.5000

7th COGNO ANNUAL SCIENTIFIC MEETING
'Translating science to patient centred trials'

FRIDAY 24th — SATURDAY 25th OCTOBER 2014
THE LANGHAM, MELBOURNE, AUSTRALIA

CONFIRMED INTERNATIONAL SPEAKERS



PROF LISA M DEANGELIS MD

CHAIR, DEPARTMENT OF NEUROLOGY, MEMORIAL SLOAN-KETTERING CANCER CENTER, USA
LILLIAN ROJTMAN BERKMAN CHAIR IN HONOR OF DR. JEROME POSNER
CO-EXECUTIVE DIRECTOR, MSKCC BRAIN TUMOR CENTER, USA



PROF MINESH P MEHTA MB ChB, FASTRO

MEDICAL DIRECTOR, MARYLAND PROTON TREATMENT CENTER, USA
ASSOCIATE DIRECTOR OF CLINICAL RESEARCH, DEPARTMENT OF RADIATION ONCOLOGY, UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE, USA



COGNO
COOPERATIVE TRIALS GROUP
FOR NEURO-ONCOLOGY

Human Genetics Society of Australasia (HGSA)

The Human Genetics Society of Australasia (HGSA) invites you to the 2014 Annual Scientific Meeting (ASM) to be held at the Hilton Adelaide from 3-6 August 2014 in Adelaide, South Australia. The HGSA ASM 2014 promises to be an exciting meeting with a strong scientific program. The theme in 2014 will be on the Changing Face of Genetic Medicine. A broad range of topics will explore the treatments of genetic disorders, the changes in practice of genetic medicine and treatment of inborn errors of metabolism through to risk prediction and genome wide detection of variation in disorders, including cancer.

The HGSA is the foremost scientific body for those working in the field of Human Genetics throughout Australia and New Zealand.



Mary-Anne Young
Vice President, Human Genetics
Society of Australasia

Medical Oncology Group of Australia (MOGA)



Our Members

Membership of the Medical Oncology Group of Australia Incorporated (MOGA) continues to grow with the number of trainees entering speciality training through the Royal Australasian College of Physicians growing annually; consultant membership running at an all-time high; and, increasing numbers of members participating in Association initiatives. As a professional membership organisation, MOGA recognises the valuable contribution our members make to the development of medical oncology practice, research and education not only in Australia but globally. Indeed, Professor Geoff Lindeman who is the distinguished recipient of the 2014 Cancer Achievement Award, has a truly unique international profile in oncology, and exemplifies the very best in Australian Medical Oncology research and practice.

Oncology Drugs and Treatments

The MOGA Oncology Drugs Working Group, set up to pursue oncology drugs and treatment matters as well as meet quarterly with the Pharmaceutical Benefits Advisory Committee (PBAC) as a clinical advisory body continues to chalk-up notable successes. The meetings with the PBAC have proven to be an important forum for addressing national oncology issues and allowing MOGA to provide

quality, up-to-date advice on clinical practice and trial developments directly to key decision-makers and ministerial advisers. The Working Group is facing an ever-expanding agenda with new items presenting for consideration at every meeting. This includes not only new oncology drugs and treatments but systemic and process issues, both old and new. For instance, the need to update the approved indications for prescription medicines, above all older oncology drugs, on the Australian Register of Therapeutic Goods. In particular, how product information for medicines could be changed over time to reflect an accumulation of evidence and changes in clinical practice.

Her2 Positive Metastatic Breast Cancer Drugs-PBAC Meeting

MOGA recently participated in a stakeholder meeting for Her2 positive metastatic breast cancer drugs convened by the PBAC. The meeting considered existing HER2 therapies (trastuzumab, lapatinib, and pertuzumab and trastuzumab emtansine) and future clinical management algorithms for metastatic breast cancer as well as non-Public Benefit Scheme (PBS) Herceptin programme eligibility criteria and PBS restrictions. The meeting agreed on how the new drugs for metastatic breast cancer could be used in keeping with best clinical practice and evolving clinical evidence; and that it was important to allow shared decision making on choice of treatment between clinicians and patients.

PBAC Meeting

There are an increasing number of oncology drugs and therapies on the agenda that are up for consideration at PBAC meetings. The PBAC recently sought the Association's advice regarding the clinical place in therapy of enzalutamide for patients with metastatic prostate cancer who have received chemotherapy and abiraterone

for patients with metastatic prostate cancer who have progressed following treatment with androgen deprivation therapy. Additional MOGA submissions have gone to the PBAC on obinutuzumab for the treatment of adult patients with untreated chronic lymphocytic leukaemia in combination with chlorambucil. Obinutuzumab was the first medicine approved with the FDA's Breakthrough Therapy Designation; Brentuximab vedotin for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma who are suitable for further systemic curative-intent salvage therapy. Trials results led to the accelerated approval of this drug by the US Food and Drug Administration in a patient population with few other alternative options.

Post-market Review of Authority Required PBS Listings

As part of the National Medicines Policy Framework, the Department of Health commenced a Post-market Review of Authority Required PBS Listings in late May. The objective of the Review is to improve patient safety and care by reducing red tape and administrative burden for health professionals. The need for the review was identified in the **Review of Chemotherapy Funding Arrangements**, where it was found that Authority Required listings caused significant regulatory burden to prescribing medical oncologists. There are currently 447 phone or complex authority required listings on the PBS. The Authority Required listings will be identified and reviewed in groups targeting those that create the greatest regulatory burden with the first priority area being Authority Required listings relating to the use of drugs in cancer. The Review will be undertaken with input from key stakeholders including the Australian Medical Association, the Royal Australian College of General Practitioner and MOGA. I have agreed to act as the MOGA representative on the Review's Reference Group.

Annual Scientific Meeting 2014 and 2015

Molecular and Immunologic Advances

into Practice is the theme of the 2014 MOGA Annual Scientific Meeting (Sydney Hilton, 6-8 August; Best of ASCO Australia 2014, 9 August) and provides an important focus for our national meeting. Professor Paul de Souza, Professor and Foundation Chair, Medical Oncology, School of Medicine University of Western Sydney and Director, Medical Oncology, Liverpool Hospital is the Meeting Convenor and along with the planning team has organised an innovative meeting program that explores many of the contemporary challenges and advances in medical oncology research, discovery and clinical practice. The 2015 ASM **Pathways in Medical Oncology - The Path Less Travelled** is now locked in to be held in Hobart from 5-7 August with Dr David Boadle from Royal Hobart Hospital acting as the Convenor.

Trainee Matters

Dr Mark Shackleton, Pfizer Australia Senior Research Fellow, Veski Innovation Fellow and Group Leader, Melanoma Research Laboratory at the Peter MacCallum Cancer Centre, has developed an innovative program for this year's **Sciences of Oncology Program** (8-9 November 2014, Melbourne) that will focus on translational sciences and research as well as current advances in cancer treatment and their relevance to the clinic, such as developmental biology, immunology, genetics, canceromics and pharmacology. This program ensures that Australian medical oncology trainees understand the sciences that underpin our speciality and, that their clinical and knowledge bases align with the rapidly changing discipline of oncology.

National Prescribing Service (NPS) - Choosing Wisely

MOGA is participating in the NPS Medicine Wise **Choosing Wisely** program which encourages clinicians, consumers and health care stakeholders to think about and discuss medical tests and procedures that may be overused, unnecessary or harmful. Over 50 specialist medical colleges and associations in the United States have signed up to this initiative, and develop and maintain their own lists of medical tests and procedures they believe should be considered carefully.


YOGA

At this year's ASM MOGA will be launching the Young Oncologists Group of Australia – YOGA. YOGA aims to provide young medical oncologists who are members of MOGA and have attained their fellowship within the last 5 years with a networking framework and assistance to facilitate their transition from advanced trainee to consultant. The Group will roll out a range of programs over the next few years but at this stage the focus is on putting in place a range of specially tailored educational and professional development initiatives.

ACORD

Planning for the 2014, 10th Anniversary **Australia and Asia Pacific Clinical Oncology Research Development Workshop (ACORD)** Workshop to be held from 14-19 September is in full swing. This program has continued to grow as a major international oncology education program with increased support from collaborating partners such as the American Association for Cancer Research, the American Society of Clinical Oncology, Cancer Council Australia and Cancer Australia

Associate Professor Gary Richardson
Chairman, Medical Oncology Group of
Australia Incorporated



Trans Tasman Radiation Oncology Group (TROG)



TROG 27th Annual Scientific Meeting

TROG's 27th Annual Scientific Meeting will be held March 24-26, 2015 at City Hall, Newcastle. TROG's ASM provides a forum for radiation oncologists, cancer care clinicians, physicists, radiation therapists, data managers, research nurses, clinical trial coordinators and personnel from allied health fields to meet and discuss TROG's current portfolio of clinical trials, potential new trials and new technologies. Our invited international speaker is Professor Kevin Franks, consultant clinical oncologist at the St. James's Institute of Oncology (SJIO) in Leeds, UK. Registrations open August at www.trog.com.au.



Presenter at the 2014 TROG ASM, Tomas Kron

Changes to TROG membership

By membership vote at the 2014 AGM, the TROG Constitution was amended and now all members qualified in their profession or specialist involved in TROG clinical trials may apply for full membership, and have full voting rights on TROG matters at Annual General Meetings. We are looking forward to the positive changes that this multidisciplinary approach will bring to TROG.

Four new trials approved for development

This year's ASM saw an unprecedented number of proposals for new trials. A total of fifteen were submitted with nine being approved for further development, these trials can be viewed in the Our Research section of www.trog.com.au.

Also unveiled at the ASM was TROG's new corporate video. The video features TROG members speaking about the organisation's efforts and can be viewed at www.trog.com.au.

Clinical trial app for patients



The free mobile app *TROG ClinTrial Refer* puts information about TROG's trials at the fingertips of patients and clinicians.

By simply choosing a disease type and nearest hospital, users can access a list of potentially suitable trials, opening up further opportunities for treatment and care. To download the app on your smartphone or tablet search for *TROG ClinTrial Refer* in the Apple App Store or on Google Play for Android. The app was funded with the 'Innovation in Cancer Clinical Trials' award TROG received at the 2013 NSW Premier's Awards for Outstanding Cancer Research.

New Consumer Advisory Panel

We are pleased to announce the formation of a new TROG committee aimed at supporting consumers who provide input into TROG's research programs. The TROG Consumer Advisory Panel (CAP) will provide support, mentoring and training to TROG consumers.

Congratulations to Tomas Kron

TROG is proud to congratulate TROG member Professor Tomas Kron, who was recognised in June for his services to medicine, research and education with an Order of Australia medal.

Joan Torony
Chief Operating Officer, TROG Cancer Research



Awareness Calendar

Date	Event	Website
2014		
August		
1 Aug	Jeans for Genes Day	http://www.jeansforgenes.org.au/-About-Us
3 - 10 Aug	National Healthy Bones Week	http://www.healthybones.com.au/
8 Aug	Dying to Know Day	http://thegroundswellproject.com/dying-to-know-day/
22 Aug	Daffodil Day	http://www.cancer.org.au/
25 Aug - 19 Sep	Fruit n Veg Month	http://healthy-kids.com.au/
September		
All month	International Gynaecological Cancer Awareness Month	www.Goforgynae.org.au
All month	Globe-athon	www.anzgog.org.au
All month	International Prostate Cancer Awareness Month	http://www.prostate.org.au/articleLive/
All month	Childhood Cancer Awareness Month	https://www.ccia.org.au/
All month	Blue September	http://www.blueseptember.org.au/
All month	Light the Night	http://www.leukaemia.org.au/
1 Sept	Gold Bow Day	https://www.thyroidfoundation.com.au/atf-awareness-events/gold-bow-day.html
15 Sep	World Lymphoma Awareness Day	
October		
26 Oct – 1 Nov	International Brain Tumour Awareness Week	http://www.theibta.org/
27 Oct	Pink Ribbon Day	http://www.pinkribbonday.com.au/
31 Oct	National Bandanna Day	https://www.canteen.org.au/
November		
All month	Movember Changing the Face of Men's Health	http://www.movember.com/
All month	Lung Awareness Month	http://lungfoundation.com.au/
17 - 23 Nov	National Cervical Cancer Awareness Week	https://accf.org.au/
17 - 23 Nov	National Skin Cancer Action Week	http://www.cancerqld.org.au/
24 - 30 Nov	Australian Mesothelioma and Asbestos Awareness Week	http://lungfoundation.com.au/

Calendar of Events

Date	Event	Venue
2014		
August		
1 - 3 Aug	Royal Australian and New Zealand College of Radiologists New Zealand Branch Annual Scientific Meeting http://www.ranzcr2014.co.nz/	Wellington, New Zealand
6 - 8 Aug	Medical Oncology Group of Australia http://moga.org.au/news-events/events/moga-asm-2014	Sydney, New South Wales
20 - 22 Aug	16th Australasian Gastro-Intestinal Trials Group Annual Scientific Meeting http://www.agitg.asnevents.com.au/	Brisbane, Queensland
21 - 23 Aug	Provincial Surgeons of Australia 50th Annual Scientific Conference and Trauma Symposium http://www.surgeons.org/media/20788092/psa_2014_provisional_program.pdf	Darwin, Northern Territory
31 Aug - 2 Sep	15th Asia-Pacific Prostate Cancer Conference 2014 http://www.prostatecancerresearch.org.au/	Melbourne, Victoria
September		
2 - 5 Sep	Australian and New Zealand Society of Palliative Medicine Conference 2014 https://www.etches.com/ehome/65181	Gold Coast, Queensland
5 Sep	The Second Victorian Psycho-Oncology Research Conference	Melbourne, Victoria
7 - 11 Sep	18th International Conference on Cancer Nursing (ICCN) http://www.isncc.org/?page=18th_ICCN	Panama City, Panama
9 - 11 Sep	Rural Health Horizons - Shaping our Future https://secure.hotelnetwork.com.au/rural_health_2014/home/program	Dubbo, New South Wales
11 - 13 Sep	3rd World Congress on Controversies in Hematology http://www.comtecmed.com/cohem/2014/	Istanbul, Turkey
14 - 19 Sep	Australia and Asia Pacific Clinical Oncology Research Development Workshop 2014 http://www.acord.org.au/	Magenta, New South Wales
26 - 30 Sep	European Society for Medical Oncology http://www.esmo.org/Conferences/ESMO-2014-Congress	Madrid, Spain
October		
9 - 11 Oct	Inaugural BreastSurgANZ Conference http://www.breastsurganz.com/events.html	Gold Coast, Queensland
9 - 11 Oct	SKMRC National Melanoma Conference 2014	Perth, Western Australia
16 - 18 Oct	BreastScreen Australia Conference 2014 http://bsaconference.com.au/	Melbourne, Victoria
16 - 18 Oct	Australasian Lung Cancer Meeting 2014 http://www.alcc.net.au/	Brisbane, Queensland
17 Oct	Cancer Institute NSW Innovations in Cancer Treatment and Care 2014 http://www.cancerinstitute.org.au/events/i/innovations-in-cancer-treatment-and-care-2014	Sydney, New South Wales
20 - 24 Oct	16th World Congress of Psycho-Oncology and Psychosocial Academy http://www.ipos2014.com/	Lisbon, Portugal
22 - 25 Oct	46th Congress of the International Society of Paediatric Oncology (SIOP) http://siop.kenes.com/	Toronto, Canada

Calendar of Events

Date	Event	Venue
2014		
23 - 25 Oct	International Society of Geriatric Oncology 2014 Conference http://www.siog.org/	Lisbon, Portugal
24 - 25 Oct	7th Cooperative Trials Group for Neuro-Oncology Annual Scientific Meeting http://cogno.org.au/content.aspx?page=cognoasm-home	Melbourne, Victoria
29 - 31 Oct	34th European Society of Surgical Oncology Congress 2014 http://www.ecco-org.eu/Events/ESSO34Baso2014.aspx	Liverpool, UK
November		
7 - 8 Nov	Combined Australia and New Zealand Colorectal Surgical Meeting http://www.cssanz.org/downloads/brochures/CR_2014_Provisional_Program.pdf	Sydney, NSW
8 - 11 Nov	15th Biennial Meeting of the International Gynaecologic Cancer Society http://www2.kenes.com/igcs/pages/home.aspx	Melbourne, Victoria
11 - 14 Nov	Australasian Leukaemia and Lymphoma Group Annual Scientific Meeting 2014 http://www.allg.org.au/events.html	Sydney, New South Wales
16 -19 Nov	Australian Health and Medical Research Congress http://www.ahmrcongress.org.au/	Melbourne, Victoria
26 - 28 Nov	Sydney Cancer Conference 2014 http://sydney.edu.au/cancer-research/SCC2014/	Sydney, New South Wales
December		
2 - 4 Dec	COSA's 41st Annual Scientific Meeting http://cosa2014.org/	Melbourne, Victoria
4 - 6 Dec	UICC World Cancer Congress	Melbourne, Victoria
2015		
March		
15 - 18 Mar	Australian Pain Society 35th Annual Scientific Meeting 2015 http://www.dconferences.com.au/aps2015/	Brisbane, Queensland
24 - 26 Mar	Trans_Tasman Radiation Oncology Group 27th Annual Scientific Meeting 2015 http://www.trog.com.au/ASM-2015	Newcastle, New South Wales
25 - 28 Mar	ANZGOG Annual Scientific Meeting 2015 http://www.anzgog.org.au/	Gold Coast, Queensland
April		
11 - 14 Apr	USANZ 68th Annual Scientific Meeting http://www.usanz2015.com/	Adelaide, South Australia
May		
4 - 8 May	Royal Australasian College of Surgeons Annual Scientific Meeting 2015 www.surgeons.org	Perth, Western Australia
29 May – 2 Jun	American Society of Clinical Oncology 51st Annual Scientific Meeting http://am.asco.org/	Chicago, USA
June		
25 - 27 Jun	MASCC/ISOO International Symposium of Supportive Care in Cancer 2015	Copenhagen, Denmark
November		
17 - 19 Nov	Save the Date! COSA's 42nd Annual Scientific Meeting 2015	Hobart, Tasmania



Clinical
Oncology
Society of
Australia

MELBOURNE

Convention
and Exhibition
Centre

www.cosa2014.org

COSA's 41st Annual Scientific Meeting



2-4 December 2014

Convenor's Welcome

COSA's Annual Scientific Meeting (ASM) is considered the premier gathering of cancer health professionals in our region each year.

Delegates to the meeting include clinicians and researchers representing medical and radiation oncologists, cancer surgeons, nurses, pharmacists, and allied health workers.

COSA is proud to announce that the 41st ASM will be held in conjunction with the UICC World Cancer Congress (WCC) in the first week of December 2014 at the Melbourne Convention and Exhibition Centre.

The COSA ASM will be held Tuesday 2nd to Thursday 4th December, and WCC 4th to 6th December, with Thursday 4th being a joint day.

The theme for COSA's 41st ASM will highlight cancer survivorship, supportive care and palliative care. Our disease theme will concentrate on lung cancer and metastases.



COSA has a strong tradition of collaborating with other societies to deliver successful conferences in areas of mutual interest.

As COSA President Elect I am excited about this opportunity and hope to share the experience with you in Melbourne in December 2014.

Associate Professor
Mei Krishnasamy

Convenor, COSA 2014 Annual Scientific Meeting

Key dates

For more information visit:
www.cosa2014.org

Symposium submission
abstracts close:
9 July 2014

Abstracts
close:
**13 August
2014**

Travel grant
applications
close:
**18 August
2014**

Early bird
registration
closes:
**5 September
2014**



**Clinical
Oncology
Society of
Australia**

MELBOURNE

Convention and
Exhibition Centre

2-4 December 2014

COSA's 41st Annual Scientific Meeting

Confirmed international speakers

As at 23 April 2014



Dr Donald Abrams
Integrative
Medicine
Specialist, UCSF
Osher Center for
Integrative
Medicine



Professor Julia Downing
Palliative Care
Nurse,
Makerere
University,
Kampala



Dr Thomas Jagoe
Cancer and
Nutrition
Expert, McGill
University



Dr Normand Laperriere
Radiation
Oncologist,
Princess
Margaret
Cancer Center



Thomas Lynch, Jr., M.D.
Director, Yale
Cancer Center
Physician-in-Chief
Smilow Cancer
Hospital at
Yale-New Haven
Hospital



Ms Mary McCabe
Survivorship
Nurse, Memorial
Sloan-Kettering
Cancer Center



Professor Harvey Pass
Surgical
Oncologist, NYU
Langone
Medical Center



Dr Sumitra Thongprasert
Medical
Oncologist,
International
Association for
the Study of
Lung Cancer
(IASLC)

Program highlights

*Please visit the
conference website
regularly for
updates on the
draft program
[www.cosa2014.org/
the-conference/program](http://www.cosa2014.org/the-conference/program)*

COSA's 41st ASM will highlight cancer survivorship, supportive care and palliative care, lung cancer and metastases. The meeting is being held in



conjunction
with the
UICC's World
Cancer
Congress (4-6
December).

- **Tuesday 2 December** – Metastases, Oligometastatic disease, Survivorship, Late effects, and Emerging technologies
- **Wednesday 3 December** – Lung cancer, Mesothelioma, Tobacco control, Integrative cancer management, Patient outcomes, and Nutrition
- **Thursday 4 December** – Sustainable systems, The financial morbidity of cancer care, Clinical trials, Hot topic – cost versus benefit, and the COSA Presidential Lecture will be delivered by Professor James Bishop AO

Thanks to our sponsors

Confirmed at 2 April 2014

Platinum:



Bristol-Myers Squibb

Gold:



Silver:



Bronze:



For more information visit: www.cosa2014.org